Syros Pharmaceuticals (SYRS) Received its Third Buy in a Row

By Jason Carr

After JMP Securities and Oppenheimer gave Syros Pharmaceuticals (NASDAQ: SYRS) a Buy rating last month, the company received another Buy, this time from Roth Capital. Analyst Jotin Marango maintained a Buy rating on Syros Pharmaceuticals today and set a price target of $12. The company’s shares opened today at $7.44, close to its 52-week low of $6.25.

Marango said:

“We believe that today’s clinical debut of the CDK7 inhibitor SY-1365 may represent a turning point for Syros. We view the dose escalation data presented favourably: so far, SY-1635 looks like a good and clean oncology drug, which now gives Syros new and material value optionality outside hematology in a wide territory of solid tumors.”

According to, Marango is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.4% and a 23.4% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.

Currently, the analyst consensus on Syros Pharmaceuticals is a Strong Buy with an average price target of $20.25, implying a 172.2% upside from current levels. In a report issued on November 1, Oppenheimer also assigned a Buy rating to the stock with a $26 price target.


See today’s analyst top recommended stocks >>

Based on Syros Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.74 million. In comparison, last year the company had a GAAP net loss of $13.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.